Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Vanda Pharmaceuticals (VNDA) over the last 15 years, with Q4 2025 value amounting to -$640000.0.

  • Vanda Pharmaceuticals' Cash from Financing Activities fell 31290.32% to -$640000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.9 million, marking a year-over-year decrease of 177483.87%. This contributed to the annual value of -$2.9 million for FY2025, which is 177483.87% down from last year.
  • As of Q4 2025, Vanda Pharmaceuticals' Cash from Financing Activities stood at -$640000.0, which was down 31290.32% from -$517000.0 recorded in Q3 2025.
  • Vanda Pharmaceuticals' 5-year Cash from Financing Activities high stood at $1.8 million for Q1 2021, and its period low was -$1.3 million during Q1 2025.
  • In the last 4 years, Vanda Pharmaceuticals' Cash from Financing Activities had a median value of $64500.0 in 2022 and averaged $101916.7.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Cash from Financing Activities surged by 28601.25% in 2021, and later tumbled by 31290.32% in 2025.
  • Quarter analysis of 4 years shows Vanda Pharmaceuticals' Cash from Financing Activities stood at $1.0 million in 2021, then plummeted by 41.88% to $605000.0 in 2022, then tumbled by 125.62% to -$155000.0 in 2024, then plummeted by 312.9% to -$640000.0 in 2025.
  • Its Cash from Financing Activities stands at -$640000.0 for Q4 2025, versus -$517000.0 for Q3 2025 and -$425000.0 for Q2 2025.